Characteristics Associated with Acute-Phase Response following First Zoledronic Acid Infusion in Brazilian Population with Osteoporosis
Table 4
Demographic and clinical characteristics of 180 patients with data on CTX according to the presence or absence of acute-phase response following zoledronic acid infusion.
Characteristics
Acute-phase response
value
Absent
Present
Patients, n (%)
132 (73.3)
48 (26.7)
Female, n (%)
107 (81.1)
40 (83.3)
0.73
Age (years); mean ± SD
71.58 ± 10.67
66.98 ± 12.77
0.016
Age categories, n (%)
≤66 years
40 (30.3%)
22 (45.8%)
0.035
67–75 years
45 (34.1%)
18 (37.5%)
>75 years
47 (35.6%)
8 (16.7%)
Oral bisphosphonate-prior use, n (%)
69 (52.3%)
13 (27.1%)
0.003
BMI (kg/m2), mean ± SD
26.27 ± 4.61
26.14 ± 4.62
0.87
Diabetes, n (%)
26 (19.7%)
7 (14.6%)
0.43
Smoking, n (%)
Never
76 (57.6%)
24 (50.0%)
0.73
Former
7 (5.3%)
3 (6.2%)
Active
48 (36.4%)
21 (43.8%)
25-Hydroxyvitamin D, median [25–75th percentile]
Baseline (ng/mL)
31.0 [25.0, 37.0]
31.0 [26.0, 37.0]
0.61
After infusion (ng/mL)
30.0 [24.0, 40.0]
30.0 [23.0, 37.0]
0.42
Group low-low × normal-normal (n)
33 × 49
17 × 13
0.93
Total calcium (mg/dL), median [25–75th percentile]
9.2 [8.9, 9.6]
9.4 [9.1, 9.7]
0.15
PTH, median [25–75th percentile]
51.0 [41.0, 63.0]
52.0 [42.0, 67.0]
0.18
eGFR level (mL/minute), mean ± SD
57.68 ± 14.80
63.09 ± 19.76
0.06
CTX, median [25–75th percentile]
Baseline, ng/mL
0.435 [0.251, 0.690]
0.531 [0.380, 0.699]
0.024
After infusion, ng/mL
0.182 [0.130, 0.264]
0.156 [0.122, 0.251]
0.26
ΔCTX median [25–75th percentile]
−53.7 [−72.1, −23.4]
−69.3 [−76.2, −49.7]
0.002
BMI, body mass index; PTH, parathyroid hormone; eGFR, estimated glomerular filtration rate, measured by CKD-EPI creatinine equation; CTX, carboxy-terminal crosslinked telopeptide of type 1 collagen; ΔCTX: delta carboxy-terminal crosslinked telopeptide of type 1 collagen.
